Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein
Hideko Kasahara, … , Charles I. Berul, Seigo Izumo
Hideko Kasahara, … , Charles I. Berul, Seigo Izumo
Published July 15, 2001
Citation Information: J Clin Invest. 2001;108(2):189-201. https://doi.org/10.1172/JCI12694.
View: Text | PDF
Article

Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein

  • Text
  • PDF
Abstract

A DNA nonbinding mutant of the NK2 class homeoprotein Nkx2.5 dominantly inhibits cardiogenesis in Xenopus embryos, causing a small heart to develop or blocking heart formation entirely. Recently, ten heterozygous CSX/NKX2.5 homeoprotein mutations were identified in patients with congenital atrioventricular (AV) conduction defects. All four missense mutations identified in the human homeodomain led to markedly reduced DNA binding. To examine the effect of a DNA binding–impaired mutant of mouse Csx/Nkx2.5 in the embryonic heart, we generated transgenic mice expressing one such allele, I183P, under the β-myosin heavy chain promoter. Unexpectedly, transgenic mice were born apparently normal, but the accumulation of Csx/Nkx2.5(I183P) mutant protein in the embryo, neonate, and adult myocardium resulted in progressive and profound cardiac conduction defects and heart failure. P-R prolongation observed at 2 weeks of age rapidly progressed into complete AV block as early as 4 weeks of age. Expression of connexins 40 and 43 was dramatically decreased in the transgenic heart, which may contribute to the conduction defects in the transgenic mice. This transgenic mouse model may be useful in the study of the pathogenesis of cardiac dysfunction associated with CSX/NKX2.5 mutations in humans.

Authors

Hideko Kasahara, Hiroko Wakimoto, Margaret Liu, Colin T. Maguire, Kimber L. Converso, Tetsuo Shioi, Weei-Yuarn Huang, Warren J. Manning, David Paul, Joel Lawitts, Charles I. Berul, Seigo Izumo

×

Figure 8

Options: View larger image (or click on image) Download as PowerPoint
Connexin 43 expression in other heart failure mouse models. (a–c) Connex...
Connexin 43 expression in other heart failure mouse models. (a–c) Connexin 43 expression in two other heart failure TG mouse models expressing either GFP protein (b) or dominant negative H-Ras[Ras(N17)] (c) were analyzed and compared with the NTG mouse (a). Heart sections were coimmunostained for connexin 43 (FITC) and α-actinin (rhodamine). Connexin 43 downregulation was observed in GFP-TG (b), which showed additional green fluorescence in both cytosol and nuclei of the GFP signal. Bars, 30 μm. (d) SDS-PAGE– and Coomassie blue–stained heart lysate from NTG (lane 1), GFP-TG (lane 2), Ras(N17)-TG (lane 3), and Csx/Nkx2.5(I183P)-TG (lane 4) mice detected high GFP expression around 29 kDa (lane 2, marked with an asterisk). (e) Western blot analysis from these lysates revealed connexin 43 downregulation in GFP-TG (lane 2) and Csx/Nkx2.5(I183P)-TG mice (lane 4). The membrane was blotted with anti-GFP and anti-FLAG for Ras(N17). Csx/Nkx2.5(I183P) expression was under detection levels (data not shown). GAPDH expression is also shown. (f) Northern blot analysis from NTG (lane 1), GFP-TG (lane 2), or Ras(N17)-TG (lane 3) showed downregulation of connexin 43 mRNA in GFP-TG the mouse (lane 2). (g) Connexin 43 expression in post-myocardial infarction heart failure mice. Noninfarcted upper septum dissected from three sham-operated (lanes 1–3), two moderate (lanes 4 and 5), and two severe (lanes 6 and 7) heart failure mice were analyzed for connexin 43 expression. No significant differences were detected among these mice.

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts